Redmile Group
No summary available yet.
Redmile is one of the most respected healthcare crossover funds in the game, but they're essentially a hedge fund with venture capital aspirations. Jeremy Green built his reputation as a sharp healthcare analyst at Citi before launching Redmile, and his European perspective on biotech gives him edge that most US-centric funds lack. The good news: they have real money ($6.5B AUM), genuine expertise, and will stick with you through public markets - rare in today's VC world. The reality check: this isn't your typical founder-friendly VC. They're investors, not advisors, and they evaluate opportunities with hedge fund rigor. If your biotech has solid science and a clear path to meaningful revenue, they're fantastic. If you need hand-holding or warm introductions to potential customers, look elsewhere.
- —Best for: Late-stage biotech with clear commercial potential and public market trajectory
- —Watch out for: Limited operational support - they're financial investors, not startup coaches
- —Known for: Deep healthcare expertise and willingness to invest through IPO and beyond
Redmile Group is a healthcare investment organization that makes venture, growth, and crossover investing across healthcare. The firm seeks to invest in healthcare, life sciences and oncology. They position themselves as domain experts who can invest from seed through public markets.
Redmile Group invests in companies and startups at Seed, Series B, Series A. The fund targets healthcare, life science, pharmaceuticals and biotechnology industry with a focus on crossover investing - they'll lead private rounds and continue investing post-IPO. Redmile Group usually invests $0-1 m on average though this appears to be outdated given their large AUM.
Jeremy Green is the founder and portfolio manager of Redmile Group. Before relocating to the US in 2004, he was managing director at Citigroup, leading the European Healthcare Research Team covering medical technology, biotech, and healthcare services. Before establishing Redmile, Jeremy co-founded Steeple Capital served as its research director, and worked as an analyst at Andor Capital.
Jeremy Green, Mike Lee co-founded the firm. Mike Lee Managing Director/Co-Founder San Francisco, California, United States Background details limited in public sources - appears to be the operational co-founder to Jeremy's investment leadership.
Rob Faulkner Managing Director at Redmile Group. Based on LinkedIn activity, he focuses on healthcare and radiology investments with expertise in medical technology trends.
Gerard van Hamel Platerink Managing Director with University of Cambridge background and prior experience at Novoste Corporation, Director Salomon Brothers, Research Analyst Kleinwort Benson, Investment Banker
Have a specific question about Redmile Group?
Ask Bernie →